These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 36305202)

  • 21. Time-dependent resistance to erythropoiesis-stimulating agent and mortality in hemodialysis patients in the Japan Dialysis Outcomes and Practice Patterns Study.
    Fujikawa T; Ikeda Y; Fukuhara S; Akiba T; Akizawa T; Kurokawa K; Saito A
    Nephron Clin Pract; 2012; 122(1-2):24-32. PubMed ID: 23486237
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Minor Elevation in C-Reactive Protein Levels Predicts Incidence of Erythropoiesis-Stimulating Agent Hyporesponsiveness among Hemodialysis Patients.
    Kimachi M; Fukuma S; Yamazaki S; Yamamoto Y; Akizawa T; Akiba T; Saito A; Fukuhara S
    Nephron; 2015; 131(2):123-30. PubMed ID: 26344924
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Factors that condition the response to erythropoietin in patients on hemodialysis and their relation to mortality.
    López-Gómez JM; Portolés JM; Aljama P
    Kidney Int Suppl; 2008 Dec; (111):S75-81. PubMed ID: 19034333
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of malnutrition-inflammation complex and responsiveness to erythropoiesis-stimulating agents in long-term hemodialysis patients.
    Rattanasompattikul M; Molnar MZ; Zaritsky JJ; Hatamizadeh P; Jing J; Norris KC; Kovesdy CP; Kalantar-Zadeh K
    Nephrol Dial Transplant; 2013 Jul; 28(7):1936-45. PubMed ID: 23045431
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Renal prognoses by different target hemoglobin levels achieved by epoetin beta pegol dosing to chronic kidney disease patients with hyporesponsive anemia to erythropoiesis-stimulating agent: a multicenter open-label randomized controlled study.
    Tsuruya K; Hayashi T; Yamamoto H; Hase H; Nishi S; Yamagata K; Nangaku M; Wada T; Uemura Y; Ohashi Y; Hirakata H;
    Clin Exp Nephrol; 2021 May; 25(5):456-466. PubMed ID: 33411115
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Erythropoietin Resistance Index and the Affecting Factors in Children with Peritoneal Dialysis.
    Pınarbaşı AS; Dursun I; Günay N; Baatar B; Yel S; Dursun J; Balaban AG; Poyrazoğlu MH; Düşünsel R
    Blood Purif; 2021; 50(6):942-951. PubMed ID: 33784664
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Influence of Altitude on Erythropoietin Resistance Index in Maintenance Hemodialysis Patients: Data from Tibetan Plateau.
    Wang Y; Dang ZH; Gan LY; Luobu C; Zhang L; Li GL; Zuo L
    Blood Purif; 2021; 50(3):364-369. PubMed ID: 33091903
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Butyrylcholinesterase level as an independent factor of erythropoiesis-stimulating agent resistance in patients on maintenance hemodialysis: a single-center cross-sectional study.
    Okamoto T; Hatakeyama S; Tanaka Y; Imanishi K; Takashima T; Saitoh F; Koie T; Suzuki T; Ohyama C
    Clin Exp Nephrol; 2018 Oct; 22(5):1174-1181. PubMed ID: 29600410
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epoetin alfa resistance in hemodialysis patients with chronic kidney disease: a longitudinal study.
    Santos EJF; Hortegal EV; Serra HO; Lages JS; Salgado-Filho N; Dos Santos AM
    Braz J Med Biol Res; 2018; 51(7):e7288. PubMed ID: 29742267
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low Lean Tissue Index and Muscle Strength Combined with High Fat Tissue Index Are Associated with Cardiovascular Disease-Related Hospitalisation in Patients on Haemodialysis.
    Tian M; Lan Q; Yuan J; He P; Yu F; Long C; Zha Y
    Cardiorenal Med; 2023; 13(1):363-371. PubMed ID: 37839407
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relationship between anti-erythropoietin receptor autoantibodies and responsiveness to erythropoiesis-stimulating agents in patients on hemodialysis: a multi-center cross-sectional study.
    Hara A; Koshino Y; Kurokawa Y; Shinozaki Y; Miyake T; Kitajima S; Toyama T; Iwata Y; Sakai N; Shimizu M; Furuichi K; Nakamura H; Wada T
    Clin Exp Nephrol; 2020 Jan; 24(1):88-95. PubMed ID: 31502102
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Associations among Erythroferrone and Biomarkers of Erythropoiesis and Iron Metabolism, and Treatment with Long-Term Erythropoiesis-Stimulating Agents in Patients on Hemodialysis.
    Honda H; Kobayashi Y; Onuma S; Shibagaki K; Yuza T; Hirao K; Yamamoto T; Tomosugi N; Shibata T
    PLoS One; 2016; 11(3):e0151601. PubMed ID: 26978524
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pleiotropic effect of erythropoiesis-stimulating agents on circulating endothelial progenitor cells in dialysis patients.
    Naito T; Shun M; Nishimura H; Gibo T; Tosaka M; Kawashima M; Ando A; Ogawa T; Sanaka T; Nitta K
    Clin Exp Nephrol; 2021 Oct; 25(10):1111-1120. PubMed ID: 34106373
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of Zinc Acetate Hydrate Supplementation on Renal Anemia with Hypozincemia in Hemodialysis Patients.
    Sato E; Sato S; Degawa M; Ono T; Lu H; Matsumura D; Nomura M; Moriyama N; Amaha M; Nakamura T
    Toxins (Basel); 2022 Oct; 14(11):. PubMed ID: 36355996
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Changes in erythropoiesis-stimulating agent responsiveness after transfer to combined therapy with peritoneal dialysis and hemodialysis for patients on peritoneal dialysis: A prospective multicenter study in Japan.
    Maruyama Y; Yokoyama K; Higuchi C; Sanaka T; Tanaka Y; Sakai K; Kanno Y; Ryuzaki M; Sakurada T; Hosoya T; Nakayama M;
    Ther Apher Dial; 2023 Aug; 27(4):735-741. PubMed ID: 36897071
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neutrophil-to-Lymphocyte Ratio and Erythropoietin Resistance among Maintenance Hemodialysis Patients.
    Zhang J; Lu X; Wang S; Li H
    Blood Purif; 2022; 51(8):708-713. PubMed ID: 34649238
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Erythropoietin resistance and survival in non-dialysis patients with stage 4-5 chronic kidney disease and heart disease.
    Guerrero-Riscos MÁ; Montes-Delgado R; Seda-Guzmán M; Praena-Fernández JM
    Nefrologia; 2012 May; 32(3):343-52. PubMed ID: 22535158
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Angiotensin II receptor blockade is associated with preserved muscle strength in chronic hemodialysis patients.
    Lin YL; Chen SY; Lai YH; Wang CH; Kuo CH; Liou HH; Hsu BG
    BMC Nephrol; 2019 Feb; 20(1):54. PubMed ID: 30764799
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical significance of a novel reticulocyte-based erythropoietin resistance index in HD patients: A retrospective study.
    Ueda E; Fujikawa T; Toya Y; Kuji T; Kakimoto-Shino M; Kawai Y; Kawano T; Azushima K; Wakui H; Tamura K
    Ther Apher Dial; 2022 Oct; 26(5):915-923. PubMed ID: 34863017
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.